Filter by
Filter by
Treatment outcomes of passive scattering proton beam therapy for stage I non-small cell lung cancer
A study by the NCC, Korea group. This study retrospectively analyzed 42 patients with stage I NSCLC treated with protos to an initial dose of 60 CGE in 4...
Hypofractionated Proton Therapy in Early Prostate Cancer: Results of a Phase I/II Trial at Loma Linda University.
A cohort of 146 patients with low-risk prostate cancer were treated to 60 Gy (cobalt Gy equivalent) of proton therapy (20 fractions of 3.0 Gy per fraction) in 4...
High-dose conformal proton therapy for clinical perineural invasion in cutaneous head and neck cancer.
Perineural invasion (PNI) is an uncommon (<5%) which refers to tumor cell invasion extensive enough to cause clinically detectable deficits of the involved...
Hypofractionated Radiation Therapy for Unresectable/Locally Recurrent Intrahepatic Cholangiocarcinoma.
This study by MGH retrospectively analyzed 66 patients with unresectable intrahepatic cholangiocarcinoma (ICC) who were treated with hypofractionated proton (32...
Hypofractionated Proton Therapy With Concurrent Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Phase I Trial From the University of Florida and Proton Collaborative Group.
Published in the Red Journal, this study reported the safety data from the first multicenter phase I trial investigating the use of hypofractionated proton...
Phase II Study of Hypofractionated Proton Beam Therapy for Hepatocellular Carcinoma.
Published by the NCC group in Korea, this study reported outcomes of 45 patients including 37 had recurrent and/or residual disease treated with PBT to a total...
Hypofractionated proton beam radiotherapy in patients with unresectable liver tumors: multi-institutional prospective results from the Proton Collaborative Group.
This study analyzed the data of 63 patients with liver tumors treated with PBT. Hypofractionated PBT resulted in excellent local control, sparing of the...